Skip to main content

Table 1 Patient Characteristics (n = 37)

From: Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

  Curative group(n = 25)Palliative group(n = 12)
Median Age (range)68.4 (32–87)72 (44–82)67 (32–87)
Gender
 Male22175
 Female1587
Performance status
 012111
 119136
 2615
 3000
Child-Pugh Classification
 A27207
 B2755
Jaundice
 yes26215
 no1147
Treatment intent
 Curative25  
 Palliative12  
Median size of the tumor (range) (mm)57 (15–140)44 (15–140)60 (22–110)
Number of tumor
 single27225
 multiple1037
TNM stage (7th UICC)
 I440
 II431
 III000
 IVa19154
 IVb1037
T stage
 1550
 2a642
 2b514
 3110
 420146
N stage
 021174
 11688
M stage
 027225
 11037
macroscopic subtype
 Mass forming (MF) type19136
 Intraductal growth (IG) type743
 Periductal infiltrating (PI) type1183
Total dose
 66.0 GyE in 10 Fraction (BED*:109.6 Gy)110
 72.6 GyE in 22 Fraction (BED:96.6 Gy)21192
 74.0 GyE in 37 Fraction (BED:88.8 Gy)523
 Other (BED < 88.8Gy)1037
Concurrent chemotherapy
 TS-115114
 Gemcitabine110
 None21138
Adjuvant Chemotherapy
 TS-11073
 Cisplatine + Gemcitabine541
 Gemcitabine422
 None18117
  1. *BED: biological effective dose (α/β = 10)